Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Giornale Italiano Di Dermatologia E Venereologia : Organo Ufficiale, Societa Italiana Di Dermatologia E Sifilografia|October 7, 2015
Paraneoplastic skin disorders: a reviewDenis Miyashiro, Jose A Sanches
Journal of the American Academy of Dermatology|September 1, 2022
An update on Epstein-Barr virus-and human T-lymphotropic virus type-1-induced cutaneous manifestations. CME Part IIAlejandro A Gru, Jose A Plaza, Jose A Sanches, et al.
Journal of the American Academy of Dermatology|August 30, 2022
An update on viral-induced cutaneous lymphoproliferative disorders. CME Part IJose A Plaza, Alejandro A Gru, Omar P Sangueza, et al.
International Journal of Dermatology|July 27, 2019
Dermoscopy of primary cutaneous B- and T-cell lymphomas and pseudolymphomas presenting as solitary nodules and tumors: a case-control study with histopathologic correlationCristián Navarrete-Dechent, Constanza Del Puerto, Álvaro Abarzúa-Araya, et al.
Dermatologic Clinics|September 24, 2021
How Coronavirus Disease 2019 Changed Dermatology Practice in 1 Year Around the World: Perspectives from 11 CountriesQisi Sun, Devon E McMahon, Pearl O Ugwu-Dike, et al.
Blood Advances|September 10, 2021
Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician's choice in cutaneous T-cell lymphoma: final dataSteven M Horwitz, Julia J Scarisbrick, Reinhard Dummer, et al.
European Journal of Cancer (Oxford, England : 1990)|June 6, 2020
Patient-reported quality of life in patients with relapsed/refractory cutaneous T-cell lymphoma: Results from the randomised phase III ALCANZA studyReinhard Dummer, Henry M Prince, Sean Whittaker, et al.
Haematologica|August 8, 2024
Distinctive genomic features of human T-lymphotropic virus type 1-related adult T-cell leukemia-lymphoma in Western populationsCaroline S Myers, Eli Williams, Carlos Barrionuevo Cornejo, et al.
Lancet (London, England)|June 11, 2017
Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trialH Miles Prince, Youn H Kim, Steven M Horwitz, et al.
European Journal of Cancer (Oxford, England : 1990)|April 1, 2021
Response to brentuximab vedotin versus physician's choice by CD30 expression and large cell transformation status in patients with mycosis fungoides: An ALCANZA sub-analysisYoun H Kim, H Miles Prince, Sean Whittaker, et al.
Pageof 1